focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,350.00
Bid: 12,348.00
Ask: 12,350.00
Change: -14.00 (-0.11%)
Spread: 2.00 (0.016%)
Open: 12,358.00
High: 12,376.00
Low: 12,276.00
Prev. Close: 12,364.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-EU seeks large AstraZeneca fine for alleged contract breach

Wed, 26th May 2021 12:27

* EU lawyer says AstraZeneca did not even try to respect
contract

* "Not a contract for the delivery of shoes" - AstraZeneca
lawyer

* EU wants a total of 120 mln doses to be delivered by end
of June
(Adds more from AstraZeneca lawyer)

By Francesco Guarascio

BRUSSELS, May 26 (Reuters) - A lawyer for the European Union
accused AstraZeneca on Wednesday of failing to respect
its contract with the 27-nation bloc for the supply of COVID-19
vaccines and asked a Belgian court to impose a large fine on the
company.

The EU took the Anglo-Swedish firm to court in April after
the drugmaker said it would aim to deliver only 100 million
doses of its vaccine by the end of June, instead of the 300
million foreseen in the supply contract.

Brussels wants the company to deliver at least 120 million
vaccines by the end of June. AstraZeneca had delivered 50
million doses by the beginning of May, just a quarter of the 200
million vaccines foreseen in the contract by then.

"AstraZeneca did not even try to respect the contract," the
EU's lawyer, Rafael Jafferali, told a Brussels court in the
first hearing on the substance of the legal case.

He said the EU was seeking 10 euros ($12.2) for each day of
delay for each dose as compensation for AstraZeneca's
non-compliance with the contract. This penalty would apply from
July 1, 2021, if the judge accepted it.

Jafferali said the EU was seeking an additional penalty of
at least 10 million euros for each breach of the contract that
the judge may decide.

A verdict is expected next month.

NOT A CONTRACT FOR SHOES

"This is not a contract for the delivery of shoes or
T-shirts," AstraZeneca's lawyer Hakim Boularbah told the court
later on Wednesday, stressing the complexity of manufacturing a
new vaccine.

The EU accusations were "shocking", Boularbah said, noting
the company had formulated its delivery targets based on early
estimates of production capacity. He added that the vaccine was
sold at cost.

AstraZeneca has repeatedly said the contract was not
binding as it only committed to make "best reasonable efforts"
in delivering doses.

Jafferali said that principle had not been respected because
the drugmaker had not delivered to the bloc 50 million doses
produced in factories that are listed in the contract as
suppliers to the EU, including 39 million doses manufactured in
Britain, 10 million produced in the United States and 1 million
in the Netherlands.

The lawyer said these doses were "diverted" to other
clients.

The company has said that doses produced in Britain were
reserved under a contract the British government signed with the
University of Oxford, which developed the vaccine.

AstraZeneca's lawyer said the British factories were
mentioned in the EU contract for information, but there was no
commitment to use them. They were expected to produce vaccines
solely for Britain until February 2021, when the company
expected to deliver 100 million doses to London. It has not yet
completed its deliveries to Britain.

Jafferali said AstraZeneca had pledged in the EU contract
not to have other engagements that would prevent it from abiding
by the terms of the deal.

The lawyer also said AstraZeneca had failed to communicate
to the EU in a timely manner the magnitude of its supply
problems because it repeatedly sent messages, including
publicly, that it was able to meet its targets, before finally
admitting there were large shortfalls in March.

The company had warned the EU in December of production
problems, but communicated only at the end of January, just
before the start of deliveries, a much larger cut than initially
expected for the first-quarter.

Boularbah said AstraZeneca had continuously kept the EU
informed about its production plans and problems.

($1 = 0.8173 euros)
(Reporting by Francesco Guarascio; Editing by Kirsten Donovan)

More News
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more
4 Apr 2024 13:09

UK shareholder meetings calendar - next 7 days

Friday 5 April 
Faron Pharmaceuticals LtdAGM
VPC Specialty Lending Investments PLCGM re capital return via B share scheme
Monday 8 April 
Premier African Minerals LtdAGM
Tuesday 9 April 
Ethernity Networks LtdEGM re board appointments and option grants
Wednesday 10 April 
Valereum PLCAGM
Wincanton PLCGM re takeover by GXO Logistics Inc
Thursday 11 April 
AstraZeneca PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.